top of page

Immunogen’s CEO comments on Q2 earnings

Mark Enyedy discusses how the launch of the antibody-drug conjugate Elahere in platinum resistant ovarian cancer is progressing.



Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page